Drug Profile

Aleniglipron - Gasherbrum Bio

Alternative Names: GSBR-1290

Latest Information Update: 26 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gasherbrum Bio
Developer Gasherbrum Bio; Structure Therapeutics
Class Antihyperglycaemics; Antiparkinsonians; Obesity therapies; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Obesity; Type 2 diabetes mellitus
Preclinical Parkinson's disease

Most Recent Events

16 Mar 2026 Structure Therapeutics anticipates a Type B End-of-Phase 2 meeting with US FDA, in the second quarter of 2026
16 Mar 2026 Pooled adverse events and efficacy data from the phase II ACCESS II, ACCESS OLE, body composition trials in Obesity released by Structure Therapeutics
16 Mar 2026 Structure Therapeutics plans a phase III trial for Obesity in USA (PO), in the second half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com